EMERGENT BIOSOLUTIONS INC. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
EMERGENT BIOSOLUTIONS INC. (EBS) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$20.30 million for the 3-month period ending 2017-03-31, per its 10-Q filed 2017-05-05.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2017-05-05
- EMERGENT BIOSOLUTIONS INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-03-31 was -$20.30M.
- EMERGENT BIOSOLUTIONS INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-12-31 was -$20.01M.
- EMERGENT BIOSOLUTIONS INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-09-30 was -$17.00M.
- EMERGENT BIOSOLUTIONS INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-06-30 was -$21.03M.
- EMERGENT BIOSOLUTIONS INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$76.26M.
- EMERGENT BIOSOLUTIONS INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$45.46M.
- EMERGENT BIOSOLUTIONS INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$210.05M.
- EMERGENT BIOSOLUTIONS INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2013 was -$67.89M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2017-03-31 | -$20.30M 10-Q · filed 2017-05-05 | -$40.32M derived: sum of 2 quarters · filed 2017-05-05 | -$57.31M derived: sum of 3 quarters · filed 2017-05-05 | -$78.35M derived: sum of 4 quarters · filed 2017-05-05 |
| 2016-12-31 | -$20.01M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | -$37.01M derived: sum of 2 quarters · filed 2017-02-28 | -$58.04M derived: sum of 3 quarters · filed 2017-02-28 | -$76.26M 10-K · filed 2017-02-28 |
| 2016-09-30 | -$17.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | -$38.03M derived: sum of 2 quarters · filed 2016-11-09 | -$56.24M 10-Q · filed 2016-11-09 | -$68.07M derived: sum of 4 quarters · filed 2017-05-05 |
| 2016-06-30 | -$21.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | -$39.25M 10-Q · filed 2016-08-05 | -$51.08M derived: sum of 3 quarters · filed 2017-05-05 | -$65.03M derived: sum of 4 quarters · filed 2017-05-05 |
| 2016-03-31 | -$18.21M 10-Q · filed 2017-05-05 | -$30.05M derived: sum of 2 quarters · filed 2017-05-05 | -$43.99M derived: sum of 3 quarters · filed 2017-05-05 | -$54.59M derived: sum of 4 quarters · filed 2017-05-05 |
| 2015-12-31 | -$11.83M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | -$25.78M derived: sum of 2 quarters · filed 2017-02-28 | -$36.38M derived: sum of 3 quarters · filed 2017-02-28 | -$45.46M 10-K · filed 2017-02-28 |
| 2015-09-30 | -$13.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | -$24.55M derived: sum of 2 quarters · filed 2016-11-09 | -$33.63M 10-Q · filed 2016-11-09 | |
| 2015-06-30 | -$10.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | -$19.68M 10-Q · filed 2016-08-05 | ||
| 2015-03-31 | -$9.08M 10-Q · filed 2016-05-06 | |||
| 2014-12-31 | -$210.05M 10-K · filed 2017-02-28 | |||
| 2013-12-31 | -$67.89M 10-K · filed 2016-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |